secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045673
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026
--------------------------------------------------------------------------------

- Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
- Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.
- Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.
- Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/0001193125-25-045673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/d924521d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer